dimiracetam

Dimiracetam is a small molecule nootropic drug of the racetam family. Originally developed as a cognition enhancer, it has shown promising efficacy in preclinical and clinical models of neuropathic pain—including nerve injury-, chemotherapy-, and osteoarthritis-induced pain. Dimiracetam acts primarily as an NMDA receptor antagonist; it inhibits NMDA-induced glutamate release in synaptosomal preparations with high potency in the spinal cord—likely via pH-sensitive GluN1/GluN2A subunit-containing isoforms. Clinical studies have demonstrated its safety and tolerability profile comparable to placebo without common side effects such as dizziness or cognitive disturbance. It has been investigated for neuropathic pain (including HIV-associated neuropathy), AIDS-related conditions, and peripheral nervous system diseases[1][4][5][7][8].

Other names

dimiracetamdihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione